Clinical Trials Logo
  1. Home
  2. Lung Neoplasms
  3. NCT05850702
  4. Details
NCT05850702 Clinical Trial

Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine

Lung Neoplasms Clinical Trial

Official title:
Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine: a Randomized, Double-blind, Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05850702
Other study ID # IIT-2022-0250
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date June 15, 2023
Est. completion date September 9, 2025

Study information
Verified date May 2023
Source RenJi Hospital
Contact Hao Zhu
Phone 008602168383702
Email zhuhaossmu@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test the effect of nebulized lidocaine on the hemodynamic response in the participant undergoing double-lumen endotracheal intubation. The main question it aims to answer is to evaluate the changes in mean arterial pressure after intubation. Participants will inhale 5ml of 2% lidocaine by nebulization15min before intubation. Researchers will compare saline group to see if saline effects

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 92
Est. completion date September 9, 2025
Est. primary completion date March 9, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. aged 18-65 years, American Society of Anesthesiologists class I-II 2. participants undergoing double-lumen endotracheal intubation under general anesthesia 3. signed informed consent and volunteered to participate in the experiment Exclusion Criteria: 1. Poor control of hypertension 2. preoperative arrhythmia 3. severe coronary artery or heart valve disease 4. sequelae of cerebrovascular accident 5. severe lung, liver, kidney and immune system diseases 6. Suspected difficult airway 7. confirmed or suspected allergy to this trial drug 8. As judged by the investigator to be ineligible for the study, such as communication impairment (language or intelligence)

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Lidocaine
inhale 5ml of 2% lidocaine by nebulization
• Saline
inhale 5ml of saline by nebulization

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
RenJi Hospital

Outcome
Type Measure Description Time frame Safety issue
Primary mean arterial pressure after intubation Immediately after intubation
See also
  Status Clinical Trial Phase
Recruiting NCT03357094 - Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function N/A
Recruiting NCT05543954 - 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients Early Phase 1
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Active, not recruiting NCT02514512 - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking N/A
Completed NCT02531737 - Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer Phase 2
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Active, not recruiting NCT02284633 - Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Completed NCT02106143 - RejuvenAir™ System Lobectomy Safety and Histology Study N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Enrolling by invitation NCT01687647 - Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure Phase 3
Completed NCT00351962 - Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours N/A
Completed NCT00243685 - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase 2/Phase 3
Completed NCT00385177 - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors Phase 1
Terminated NCT00356525 - Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor Phase 2
Completed NCT00129844 - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer Phase 2
Withdrawn NCT00090701 - A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01789229 - Establishment of a Tumor Bank for Tissue Samples